HeartFlow, Inc. operates as a global medical technology firm, specializing in providing non-surgical solutions for the diagnosis and ongoing management of coronary ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Bank of New York Mellon Corp bought a new stake in shares of Heartflow, Inc. (NASDAQ: HTFL) during the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund bought 650,849 shares of the company's stock, valued at approximately $19,096,000. Bank of New York Mellon Corp owned
BlackRock Inc. acquired a new stake in Heartflow, Inc. (NASDAQ: HTFL) in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 5,197,747 shares of the company's stock, valued at approximately $152,502,000. BlackRock Inc. owned 6.03% of Heartflow at the end of
FUSION trial presented at ESC and published in Journal of the American College of Cardiology demonstrates adding non-invasive lesion-specific physiology resolves critical diagnostic uncertainty, supporting Appropriate Use Criteria for cath lab referrals FUSION trial presented at ESC and published in Journal of the American College of Cardiology demonstrates adding non-invasive lesion-specific physiology resolves critical diagnostic uncertainty, supporting Appropriate Use Criteria for cath lab referrals
SAN FRANCISCO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing and managing coronary artery disease (CAD), today announced that members of management will participate in a fireside chat at the upcoming Wells Fargo 21st Annual Healthcare Conference. The fireside chat, which will include a slideshow presentation followed by a question-and-answer session, will take place in Boston on Wednesday, September 9, 2026, at 3:45 p.m. ET / 12:45 p.m. PT.
The executive sold 9,219 shares at $41.23 per share on August 17, 2026, generating ~$380,100. The transaction reduced the insider's direct equity position by 10%, while total beneficial ownership decreased by 4%.
Bank of New York Mellon Corp bought a new stake in shares of Heartflow, Inc. (NASDAQ: HTFL) during the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund bought 650,849 shares of the company's stock, valued at approximately $19,096,000. Bank of New York Mellon Corp owned
BlackRock Inc. acquired a new stake in Heartflow, Inc. (NASDAQ: HTFL) in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 5,197,747 shares of the company's stock, valued at approximately $152,502,000. BlackRock Inc. owned 6.03% of Heartflow at the end of
FUSION trial presented at ESC and published in Journal of the American College of Cardiology demonstrates adding non-invasive lesion-specific physiology resolves critical diagnostic uncertainty, supporting Appropriate Use Criteria for cath lab referrals FUSION trial presented at ESC and published in Journal of the American College of Cardiology demonstrates adding non-invasive lesion-specific physiology resolves critical diagnostic uncertainty, supporting Appropriate Use Criteria for cath lab referrals
SAN FRANCISCO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing and managing coronary artery disease (CAD), today announced that members of management will participate in a fireside chat at the upcoming Wells Fargo 21st Annual Healthcare Conference. The fireside chat, which will include a slideshow presentation followed by a question-and-answer session, will take place in Boston on Wednesday, September 9, 2026, at 3:45 p.m. ET / 12:45 p.m. PT.
The executive sold 9,219 shares at $41.23 per share on August 17, 2026, generating ~$380,100. The transaction reduced the insider's direct equity position by 10%, while total beneficial ownership decreased by 4%.
HeartFlow delivered a convincing Q2 with 48% sales growth and gross margins rising to 83%, driving strong market optimism. The company raised full-year revenue guidance to $246–$250 million, though the outlook appears conservative given recent momentum and sequential growth. Shares now trade at 13x sales, supported by accelerating topline growth, expanding plaque-related revenue, and commercial adoption of its non-invasive cardiac solution.
Heartflow's AI-powered platform could save countless lives. The company is growing at an impressive clip.
HeartFlow Inc. (NASDAQ:HTFL) shares are trading sharply higher Friday afternoon after the company reported better-than-expected second-quarter adjusted EPS results and raised its full-year financial outlook.
HeartFlow, Inc. (HTFL) Q2 2026 Earnings Call Transcript
Heartflow NASDAQ: HTFL reported second-quarter revenue of $64.1 million, up 48% from a year earlier, as growth in its Plaque Analysis offering, durable FFR-CT utilization and continued expansion of the coronary CT angiography, or CCTA, market supported results.
HeartFlow (HTFL) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $1.46 per share a year ago.
SAN FRANCISCO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing coronary artery disease (CAD), today reported financial results for the second quarter ended June 30, 2026.
After a week of wild swings that rattled portfolios and left investors guessing, Wall Street analysts are already reshuffling their ratings on Friday morning, with some surprising cuts and upgrades across sectors from utilities to gaming that could reshape how you think about your positions.
The medical technology company reported a notable insider sale in recent filings.
I recommend a buy rating for HeartFlow, Inc. due to its strong clinical workflow integration and expanding product suite. HTFL's AI-enabled platform, anchored by FFRCT and Plaque Analysis, drives adoption, monetization, and workflow efficiency in coronary artery disease diagnosis. Plaque Analysis, validated and soon to have its own billing code, broadens HTFL's addressable market and supports incremental revenue growth from existing CCTA scans.
Heartflow Plaque Staging TM , the only staging tool based on total plaque volume * , is now included with every Heartflow Plaque Analysis Data from over 36,000 patients validate the accuracy, reproducibility and utility of Heartflow Plaque Analysis SAN FRANCISCO, July 09, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced eight new datasets from clinical studies spanning more than 36,000 patients will be presented at the Society of Cardiovascular Computed Tomography (SCCT) 2026 Annual Scientific Meeting taking place July 9-12, 2026 in San Diego. These studies reveal over 50% of symptomatic patients with zero coronary artery calcium (CAC) harbor significant non-calcified plaque that traditional CAC scoring cannot detect.
Heartflow uses artificial intelligence to transform coronary imaging into actionable diagnostic data for heart disease. Omeros is launching its first commercial product, Yartemlea, while maintaining a pipeline focused on rare diseases.
Heartflow leverages AI-enabled software to dominate the non-invasive coronary diagnostic market, backed by a stable base of over 1,450 accounts. Iovance Biotherapeutics is pioneering personalized TIL therapies for cancer, backed by centralized manufacturing and significant revenue growth from its lead products.
AI-powered diagnostics meet global oncology innovation as two medical disruptors post strong revenue growth, yet face distinct risk and valuation profiles.
In the first quarter of 2026, Baron Discovery Fund declined 10.65% (Institutional Shares), trailing the Russell 2000 Growth Index by 7.84% due to significant underperformance in the software sector. Advanced Energy Industries, Inc.'s stock rose during the quarter as the market began to appreciate the strength that the company would see in both its data center and semiconductor end markets. Baron Discovery Fund sold its investment in Intapp, Inc. in the quarter as the team believes that its other software holdings have better overall competitive advantages.
